Alzheimer's disease research and treatmentsAmyloidosis: Diagnosis, Treatment, OutcomesMultiple Sclerosis Research Studies

Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab

N. Koglin, A. Jovalekic, M. Chapleau, J. Seidel, M. Ritter, Eva Bickel, N. Kiessling, E. MacSweeney, A. Stephens, A. Mueller

2026.4.1NUKLEARMEDIZIN-NUCLEAR MEDICINE

DOI: 10.1055/s-0046-1818220

Abstract

Abstract is not available.

Citation format

KOGLIN, N., et al. Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2026, 65(02): 119.